Emil Rozenek

Emil Rozenek

Auto-generated profile, based on publicly available information

Emil Rozenek

Endocrinology Department, Bielanski Hospital, Warsaw. Poland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2020 in Psychiatria Polska
Verified
Journal Article
Open access
EREmil Rozenek
Emil Rozenek
WOWiktor Orlof
Wiktor Orlof
ZNZuzanna Nowicka
Zuzanna Nowicka
Karolina WilczyńskaKarolina Wilczyńska
Karolina Wilczyńska
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Niemożność mówienia w pewnych sytuacjach − tak najkrócej można scharakteryzować mutyzm wybiórczy (ang. Selective mutism, SM), który według najnowszych klasyfikacji (DSM-V, ICD-11) należy do spektrum zaburzeń lękowych. Pojawienie się mutyzmu wybiórczego w okresie wczesnodziecięcym może zaburzać dalszy rozwój, a także niekorzystnie wpływać na osiągnięcia edukacyjne. Zarówno psychiatrzy, jak i lekarze innych specjalizacji, logopedzi, pielęgniarki i nauczyciele powinni posiadać odpowiednią wiedzę na temat tego zaburzenia, ponieważ wcześnie podjęte leczenie wiąże się z lepszym rokowaniem. Celem niniejszego przeglądu literatury jest przybliżenie współczesnego spojrzenia na stosunkowo rzadki zespół psychopatologiczny jakim jest mutyzm wybiórczy. W świetle najnowszych badań dotyczących etiologii SM sam objaw mutyzmu wydaje się być jedynie wykładnikiem kryjącej się pod nim heterogennej grupy zaburzeń. Opierając się na psychopatologii rozwoju można wnioskować, że wzajemne powiązania między piętrzącymi się nieprawidłowościami sprzyjają ujawnieniu się SM w przełomowym okresie życia. Złożoność etiologiczna sugeruje multimodalne podejście do pacjenta w procesie diagnostyczno-terapeutycznym, co jest postulowane przez wielu autorów.

1 September 2019 in Archives of Industrial Hygiene and Toxicology
Verified
Journal Article
Open access
PDF file
EREmil Bartosz Rozenek
Emil Bartosz Rozenek
MGMonika Górska
Monika Górska
KWKarolina Wilczyńska
Karolina Wilczyńska
NWNapoleon Waszkiewicz
Napoleon Waszkiewicz
An increasing number of people, students in particular, seek substances that improve their cognitive functioning. The most popular group of pharmacological cognitive enhancers (PCEs) are stimulants. Available studies suggest a small beneficial effect of methylphenidate and amphetamine on memory, executive functions, and processing speed. However small, this effect can make the difference between success and failure. In recent years, research has focused on the additional beneficial effect on the emotional state, increased motivation, and placebo-induced cognitive enhancement. This paper briefly reviews the latest and most important research on the relationship between popular stimulants and cognitive enhancement. One cannot understand this relationship without understanding the Yerkes-Dodson law, which explains the relationship between the degree of arousal and performance. It suggests that the effect of stimulants is a dose-dependent continuum. This law has repeatedly been confirmed by studies in which an optimal level of psychoactivation for cognitive enhancement was obtained with low stimulant doses, whereas exceeding the effective dose resulted in cognitive deficits, psychomotor agitation, and addiction. A separate section has been devoted to modafinil, an increasingly popular stimulant that differs from the rest in neurochemical profile and behavioural effects.

21 October 2019 in Przeglad Epidemiologiczny
Verified
Journal Article
Closed access
ERE. B. Rozenek
E. B. Rozenek
KWK. Wilczyńska
K. Wilczyńska
MGM. Górska
M. Górska
NWN. Waszkiewicz
N. Waszkiewicz
In Poland, an increasing number of psychoactive substances are becoming prohibited by law as psychotropic or narcotic substances, or as new psychoactive substances (NPSs). Owing to the enormous technological possibilities offered by today’s science, synthesis of new derivatives of prohibited compounds is no longer a problem. The moment a dangerous substance is outlawed, new designer drugs (in Poland known as ‘dopalacze’) appear on the market. An amendment to the Act on Counteracting Drug Addiction issued in July 2018 made it possible for the NPS to be considered drugs by law. Synthetic cannabinoids and cathinone derivatives make up the majority of NPSs identified by the authorities in Poland. Synthetic cannabinoids which can, unlike cannabinoid receptor agonists of plant origin, cause death by somatic toxicity, are particularly dangerous. The ability to quickly recognize poisoning with synthetic opioids is crucial, since an antidote reversing the depressive effect of opioids on the respiratory center can be administered. This work collects the most important and up-to-date information on designer drugs, based on reports and articles published between 2015 and 2019. The covered aspects include: the current definition of designer drugs in relation to the Polish law, their exact division due to the clinical effects they cause and the description of the threats they pose. Emphasis was given to the current situation of the designer drug market in Poland.


15 June 2023 in Wiedza Medyczna
Verified
Journal Article
Open access
PDF file
EREmil Rozenek
Emil Rozenek
WMWaldemar Misiorowski
Waldemar Misiorowski
Hypercalcemia affects approximately 1% of the worldwide population. This electrolyte abnormality is frequent both in out and inpatients (varies from 0,17 to 5% in hospitalized, however incidence increases even up to 7,5% in emergency departments in some populations). Primary hyperparathyroidism (PHPT) and hypercalcemia of malignancy (HCM), account for more than 90 percent of all causes of hypercalcemia. Other causes of hypercalcemia, such as vitamin D intoxication, granulomatous disorders, milk-alkali syndrome, medications, familial hypocalciuric hypercalcemia and immobilization amount to less than 10% of all causes of hypercalcemia. However, once primary hyperparathyroidism or cancer has been excluded, other causes of hypercalcemia, often life-threatening and requiring appropriate causal management, should be considered. Considering rare etiologies is important, nevertheless, when primary hyperparathyroidism or malignancy do not account for the hypercalcemia. The review describes patophysiology, symptoms and diagnostic approach to the most relevant causes of hypercalcemia.